Cheng Fang, Xu Qiling, Li Qiang, Cui Zheng, Li Weiming, Zeng Fang
Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, China.
Front Oncol. 2023 Feb 6;13:1113462. doi: 10.3389/fonc.2023.1113462. eCollection 2023.
Dasatinib, a second-generation tyrosine kinase inhibitor, is recommended as first-line treatment for patients newly diagnosed with chronic myeloid leukemia (CML) and second-line treatment for those who are resistant or intolerant to therapy with imatinib. Dasatinib is superior to imatinib in terms of clinical response; however, the potential pulmonary toxicities associated with dasatinib, such as pulmonary arterial hypertension and pleural effusion, may limit its clinical use. Appropriate management of dasatinib-related severe events is important for improving the quality of life and prognosis of patients with CML. This review summarizes current knowledge regarding the characteristics, potential mechanisms, and clinical management of adverse reactions occurring after treatment of CML with dasatinib.
达沙替尼是一种第二代酪氨酸激酶抑制剂，被推荐作为新诊断慢性髓性白血病（CML）患者的一线治疗药物，以及对伊马替尼治疗耐药或不耐受患者的二线治疗药物。在临床反应方面，达沙替尼优于伊马替尼；然而，与达沙替尼相关的潜在肺部毒性，如肺动脉高压和胸腔积液，可能会限制其临床应用。妥善处理与达沙替尼相关的严重事件对于提高CML患者的生活质量和预后至关重要。本综述总结了目前关于达沙替尼治疗CML后发生不良反应的特征、潜在机制及临床处理的相关知识。
